Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Orchard Therapeutics Plc ADR (NQ: ORTX ) N/A UNCHANGED Last Price Updated: 4:00 PM EST, Jan 23, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Orchard Therapeutics Plc ADR < Previous 1 2 Next > Orchard Therapeutics Announces New Clinical and Pre-clinical Data at ASGCT 2023 May 03, 2023 From Orchard Therapeutics (Europe) Limited Via GlobeNewswire Orchard Therapeutics to Present at Guggenheim Genomic Medicines and Rare Disease Day March 30, 2023 From Orchard Therapeutics (Europe) Limited Via GlobeNewswire Orchard Therapeutics Completes ADS Ratio Change March 10, 2023 From Orchard Therapeutics (Europe) Limited Via GlobeNewswire Orchard Therapeutics Provides Business Update and Reports 2022 Financial Results March 06, 2023 From Orchard Therapeutics (Europe) Limited Via GlobeNewswire Orchard Therapeutics Announces Strategic Financing Totalling up to $188 Million March 06, 2023 From Orchard Therapeutics (Europe) Limited Via GlobeNewswire Orchard Therapeutics to Present at Multiple Investor Conferences in March 2023 March 03, 2023 From Orchard Therapeutics (Europe) Limited Via GlobeNewswire Orchard Therapeutics Announces Agreement Enabling Reimbursed Access to Libmeldy for All Eligible MLD Patients in Sweden February 27, 2023 From Orchard Therapeutics (Europe) Limited Via GlobeNewswire Orchard Therapeutics Announces Presentation of Updated Integrated Analysis of OTL-200 in MLD and Reports Progress with Newborn Screening Efforts at the 19th Annual WORLDSymposium™ February 24, 2023 From Orchard Therapeutics (Europe) Limited Via GlobeNewswire Orchard Therapeutics Announces Proposed ADS Ratio Change February 10, 2023 From Orchard Therapeutics (Europe) Limited Via GlobeNewswire Orchard Therapeutics Announces Comprehensive Presence at 19th Annual WORLDSymposium February 08, 2023 Four oral presentations and 11 posters highlight transformative potential of HSC gene therapy and newborn screening to address severe neurometabolic diseases From Orchard Therapeutics (Europe) Limited Via GlobeNewswire Orchard Therapeutics Highlights Recent Progress Across HSC Gene Therapy Portfolio and Outlines Key 2023 Milestones January 09, 2023 From Orchard Therapeutics (Europe) Limited Via GlobeNewswire Orchard Therapeutics Announces U.S. FDA Clearance of IND Application for OTL-203 in MPS-IH January 05, 2023 Global registrational trial expected to commence in the second half of 2023 From Orchard Therapeutics (Europe) Limited Via GlobeNewswire Orchard Therapeutics Announces Promising Early Neurocognitive Outcomes from Ongoing Proof-of-concept Study of OTL-201 in MPS-IIIA December 12, 2022 From Orchard Therapeutics (Europe) Limited Via GlobeNewswire Orchard Therapeutics Announces Swissmedic Validation of the Marketing Authorization Application for Libmeldy (atidarsagene autotemcel) December 01, 2022 From Orchard Therapeutics (Europe) Limited Via GlobeNewswire Orchard Therapeutics Reports Third Quarter 2022 Financial Results and Reviews Recent Business Highlights November 14, 2022 From Orchard Therapeutics (Europe) Limited Via GlobeNewswire Orchard Therapeutics to Present at Multiple Investor Conferences in November 2022 November 08, 2022 From Orchard Therapeutics (Europe) Limited Via GlobeNewswire Orchard Therapeutics to Webcast Conference Call of Third Quarter 2022 Financial Results November 07, 2022 From Orchard Therapeutics (Europe) Limited Via GlobeNewswire Orchard Therapeutics Announces First Neurocognitive Data from OTL-201 Study in MPS-IIIA Accepted for Oral Presentation at ASH 2022 November 03, 2022 Company to host KOL conference call and webcast on Monday, December 12 at 5:00 p.m. EST From Orchard Therapeutics (Europe) Limited Via GlobeNewswire Orchard Announces Multiple Presentations at 2022 ESGCT Annual Congress Showing the Potential of HSC Gene Therapy in Several Therapeutic Areas October 10, 2022 From Orchard Therapeutics (Europe) Limited Via GlobeNewswire < Previous 1 2 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.